Announcements
Open Access
Commentary
SARS-CoV-2 vaccination in gynecologic oncology
Zachary Alholm1,*, Daniel Spinosa2, Rebecca A. Previs3, Stephanie L. Shuey4, David M. O’Malley5, Leslie Randall6, Brian Slomovitz7, Bradley J. Monk8
Show Less
1
Department of Obstetrics and Gynecology, University of Arizona-Phoenix, Phoenix, AZ 85004, USA
2
Department of Obstetrics and Gynecology, Duke University Health System, Durham, NC 27710, USA
3
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA
4
Department of Pharmacy, Duke University Medical Center, Durham, NC 27710, USA
5
Division of Gynecology Oncology, The Ohio State University and the James Comprehensive Cancer Center, Columbus, OH 43210, USA
6
Division of Gynecologic Oncology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23284, USA
7
Division of Gynecology Oncology, Broward Health, Florida International University, Fort Lauderdale, FL 33199, USA
8
Arizona Oncology (US Oncology Network), University of Arizona, Creighton University, Phoenix, AZ 85721, USA
Eur. J. Gynaecol. Oncol. 2021, 42(2), 402–404;
https://doi.org/10.31083/j.ejgo.2021.02.2491
Submitted: 13 April 2021 | Accepted: 15 April 2021 | Published: 15 April 2021
Abstract
No abstract present.